Taiwan, Feb. 2 -- based startup Anbogen Therapeutics, a clinical-stage biotechnology company specialising in groundbreaking cancer drug development, has announced the successful completion of its Series A funding round.

The lead investor is China Development Industrial Bank (CDIB), with significant contributions from Taian Venture Capital, Maxpro and the National Development Fund (Business Angel Investment Programme, and Implementation Project for Strengthening Investment in SMEs), with a total investment of approximately $12.5 million.

The raised capital will be directed towards the ongoing development of Anbogen's two main drug candidates, ABT-101 and ABT-301. Both of these candidate drugs were supported by the National Research Progr...